Stabilized Soluble Alpha-Synuclein Oligomer Vaccine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic methods for α-synuclein-related disorders, such as Parkinson's disease and dementia with Lewy bodies, lack effective tools for early detection and treatment, as they primarily focus on symptomatic relief rather than addressing the underlying disease processes, and there is a need for improved diagnostic assays and treatments that target the accumulation of insoluble α-synuclein aggregates.
Innovation Solution
Development of vaccines and antibodies targeting stabilized soluble α-synuclein oligomers, which have a lower formation rate to non-soluble aggregates, for use in therapeutic and diagnostic methods, including active and passive immunization, to delay disease onset or treat α-synuclein-related disorders by binding to soluble α-synuclein and potentially reducing intracellular levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current diagnostic and therapeutic methods focus on symptomatic relief, then ease of operation is improved, but the ability to address underlying disease processes deteriorates
Solution Approach 1:
The vaccine administers stabilized soluble α-synuclein oligomers before substantial brain damage occurs, enabling early intervention that addresses the underlying disease process rather than just symptomatic relief. This preliminary action prevents the formation of insoluble aggregates that cause neurodegeneration.
Solution Approach 2:
The stabilized soluble oligomers serve as an intermediary that bridges the gap between diagnostic detection and therapeutic intervention. These oligomers can be detected as biomarkers and simultaneously used as vaccine antigens to induce protective immune responses, combining diagnostic and therapeutic functions.
2Ease of operation
If current methods primarily focus on symptomatic relief, then ease of operation is improved, but measurement precision for early detection deteriorates
Solution Approach 1:
The patent utilizes detectable markers that can be detected by imaging or other detection methods to visualize and measure the presence and distribution of stabilized soluble oligomers in the brain, enabling precise early detection of α-synuclein pathology before substantial damage occurs.
Solution Approach 2:
The patent replaces conventional mechanical or chemical detection methods with advanced imaging and detection technologies that can specifically identify stabilized soluble oligomers in vivo, significantly improving measurement precision for early detection of α-synuclein-related disorders.
3Reliability
If stabilized soluble α-synuclein oligomers are used as vaccine antigens, then reliability of treating underlying disease is improved, but device complexity increases
Solution Approach 1:
The patent modifies the physical and chemical parameters of α-synuclein oligomers by stabilizing them in a soluble state, preventing their conversion to insoluble aggregates. This parameter change enables the oligomers to serve as effective vaccine antigens that induce protective immune responses while maintaining solubility and detectability.
Solution Approach 2:
The vaccine system employs composite structures combining stabilized soluble oligomers with detectable markers and adjuvants, creating a multifunctional therapeutic agent that provides both diagnostic and therapeutic benefits while managing system complexity through integrated design.
4Duration of action of stationary object
If stabilized soluble oligomers with lower formation rate are used, then duration of action is improved by delaying disease onset, but productivity of preventing aggregate formation deteriorates
Solution Approach 1:
The vaccine administers stabilized soluble oligomers in advance to prevent the natural progression to insoluble aggregate formation. By acting preliminarily before substantial brain damage occurs, the treatment extends the duration of action and delays disease onset, even though the rate of preventing aggregate formation may be gradual.
Solution Approach 2:
The patent employs dynamic stabilization of oligomers, where the stabilized soluble oligomers can dynamically interact with and prevent the formation of insoluble aggregates over time. This dynamic approach allows the system to adapt and maintain protective effects throughout the disease progression timeline.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of stabilized soluble α-synuclein oligomers in vaccines and antibodies provides a novel approach to diagnose and treat α-synuclein-related disorders by targeting toxic forms of α-synuclein, potentially delaying disease progression and providing early intervention before substantial brain damage occurs.
Implementation Method 1
an antibody binds soluble α-synuclein
Implementation Method 2
isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form
Data Source
Figure 1~2A
Figure 2B~3
Figure 4~5
AI summary
A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual binds soluble α-synuclein. Methods for delaying an onset of, for treatment or for prevention of an α-synuclein-related disorder employ the vaccine or antibody. Methods of detecting α-synuclein oligomers employ the antibody.